The F.D.A. Suspends Use of Glaxo Antibody Drug in the U.S.
Manufacturers said lab testing revealed that the authorized dosage of the drug was not sufficiently potent against BA.2.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.